Effect of Flt3 ligand gene transfer in experimental pancreatic cancer

International Journal of Colorectal Disease

Volumn 22, Issue 2, 2007, Pages 215-223

  Ryschich, E ^a   Huszty, G ^a   Wentzensen, N ^a   Schmidt, E ^a   Knaebel, H P ^a   Encke, J ^a   Marten A ^a   Buchler M W ^a   Schmidt, Jan ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Experimental therapy; Flt3 ligand; Pancreatic cancer

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; B7 ANTIGEN; BETA GALACTOSIDASE; CHOLESTEROL; COMPLEMENTARY DNA; FLT3 LIGAND; LIPOSOME; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTATION; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; GENE CONSTRUCT; GENE SEQUENCE; GENE TRANSFER; GENETIC TRANSFECTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MALE; MOLECULAR CLONING; MOUSE; NATURAL KILLER CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; RAT; RAT STRAIN; RNA EXTRACTION; SPLEEN; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME; VASCULAR TUMOR;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; GENE TRANSFER TECHNIQUES; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MALE; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; PANCREATIC NEOPLASMS; RATS; RATS, INBRED LEW; SEQUENCE ANALYSIS, DNA;

EID: 33845695499     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-006-0118-5     Document Type: Article

References (51)

1. Michaud DS (2004) Epidemiology of pancreatic cancer. Minerva Chir 59:99-111
2. Lim JE, Chien MW, Earle CC (2003) Prognostic factors following curative resection for pancreatic adenocarcinoma. Ann Surg 237:74-85
3. Neoptolemos JP, Stocken DD, Dunn JA, Almond J, Beger HG, Pederzoli P, Bassi C, Dervenis C, Fernandez Cruz L, Lacaine F, Buell MG, Dean DC, Adab FA, Sutton R, Imrie C, Ihse I, Tihanyi T, Olah A, Pedrazzoli S, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg 234:758-768
4. MacKenzie MJ (2004) Molecular therapy in pancreatic adenocarcinoma. Lancet Oncol 5:541-549
5. Picozzi VJ, Traverso LW (2004) The Virginia Mason approach to localized pancreatic cancer. Surg Oncol Clin N Am 13:663-674
6. Nukui Y, Picozzi VJ, Traverso LW (2000) Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 179:367-371
7. Guermonprez P, Valladeau J, Zitvogel L, Thery C, Amigorena S (2002) Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol 20:621-667
8. Pecher G, Haring A, Kaiser L, Thiel E (2002) Mucin gene (MUC1) transfected dendritic cells as vaccine: Results of a phase I/II clinical trial. Cancer Immunol Immunother 51:669-673
9. Morse MA, Nair SK, Boczkowski D, Tyler D, Hurwitz HI, Proia A, Clay TM, Schlom J, Gilboa E, Lyerly HK (2002) The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 32:1-6
10. Gjertsen MK, Buanes T, Rosseland AR, Bakka A, Gladhaug I, Soreide O, Eriksen JA, Moller M, Baksaas I, Lothe RA, Saeterdal I, Gaudernack G (2001) Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer 92:441-450
11. Karsunky H, Merad M, Cozzio A, Weissman IL, Manz MG (2003) Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J Exp Med 198:305-313
12. Lyman SD, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS (1995) Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene 10:149-157
13. Dong J, McPherson CM, Stambrook PJ (2002) Flt-3 ligand: A potent dendritic cell stimulator and novel antitumor agent. Cancer Biol Ther 1:486-489
14. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman SD, Shortman K, McKenna HJ (1996) Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified. J Exp Med 184:1953-1962
15. Antonysamy MA, Thomson AW (2000) Flt3 ligand (FL) and its influence on immune reactivity. Cytokine 12:87-100
16. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625-631
17. Brasel K, McKenna HJ, Morrissey PJ, Charrier K, Morris AE, Lee CC, Williams DE, Lyman SD (1996) Hematologic effects of flt3 ligand in vivo in mice. Blood 88:2004-2012
18. Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL (1998) Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: Implications for anti-cancer and anti-viral therapy. J Immunol 161:2817-2824
19. Peron JM, Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3-ligand administration inhibits liver metastases: Role of NK cells. J Immunol 161:6164-6170
20. Silver DF, Hempling RE, Piver MS, Repasky EA (2000) Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol 77:377-382
21. Averbook BJ, Schuh JL, Papay R, Maliszewski C (2002) Antitumor effects of Flt3 ligand in transplanted murine tumor models. J Immunother 25:27-35
22. Furumoto K, Soares L, Engleman EG, Merad M (2004) Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 113:774-783
23. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR (1998) FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res 58:380-383
24. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K (1997) Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57:3511-3516
25. Chakravarty PK, Alfieri A, Thomas EK, Beri V, Tanaka KE, Vikram B, Guha C (1999) Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer. Cancer Res 59:6028-6032
26. Silver DF, Hempling RE, Piver MS, Repasky EA (2000) Flt-3 ligand inhibits growth of human ovarian tumors engrafted in severe combined immunodeficient mice. Gynecol Oncol 77:377-382
27. Ciavarra RP, Somers KD, Brown RR, Glass WF, Consolvo PJ, Wright GL, Schellhammer PF (2000) Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer. Cancer Res 60:2081-2084
28. Ciavarra RP, Holterman DA, Brown RR, Mangiotti P, Yousefieh N, Wright GL Jr, Schellhammer PF, Glass WF, Somers KD (2004) Prostate tumor microenvironment alters immune cells and prevents long-term survival in an orthotopic mouse model following flt3-ligand/CD40-ligand immunotherapy. J Immunother 27:13-26
29. Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schellhammer PF, Somers KD (2003) Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother 52:535-545
30. Somers KD, Brown RR, Holterman DA, Yousefieh N, Glass WF, Wright GL Jr, Schellhammer PF, Qian J, Ciavarra RP (2003) Orthotopic treatment model of prostate cancer and metastasis in the immunocompetent mouse: Efficacy of flt3 ligand immunotherapy. Int J Cancer 107:773-780
31. Favre-Felix N, Martin M, Maraskovsky E, Fromentin A, Moutet M, Solary E, Martin F, Bonnotte B (2000) Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer 86:827-834
32. Borges L, Miller RE, Jones J, Ariail K, Whitmore J, Fanslow W, Lynch DH (1999) Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J Immunol 163:1289-1297
33. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K (1997) Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57:3511-3516
34. Miller G, Pillarisetty VG, Shah AB, Lahrs S, DeMatteo RP (2003) Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. J Immunol 170:3554-3564
35. Yanagi K, Nagayama Y, Nakao K, Saeki A, Matsumoto K, Ichikawa T, Ishikawa H, Hamasaki K, Ishii N, Eguchi K (2003) Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo. Int J Oncol 22:345-351
36. Dong J, Bohinski RJ, Li YQ, Van Waes C, Hendler F, Gleich L, Stambrook PJ (2003) Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer. Cancer Gene Ther 10:96-104
37. Braun SE, Chen K, Blazar BR, Orchard PJ, Sledge G, Robertson MJ, Broxmeyer HE, Cornetta K (1999) Flt3 ligand antitumor activity in a murine breast cancer model: A comparison with granulocyte-macrophage colony-stimulating factor and a potential mechanism of action. Hum Gene Ther 10:2141-2151
38. Yang Q, Yang G, Wei L, Jia F, Wu M, Guo Y (2002) Gene transfer of murine Flt3 ligand mediated by adenoviral vector efficiently induces growth inhibition of murine liver cancer. Zhonghua Yi Xue Za Zhi 82:775-779
39. Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: A journey from laboratory to clinic. Nat Immunol 5:7-10
40. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238
41. Frohman MA, Dush MK, Martin GR (1988) Rapid production of full-length cDNAs from rare transcripts: Amplification using a single gene-specific oligonucleotide primer. Proc Natl Acad Sci U S A 85:8998-9002
42. Pettengill OS, Faris RA, Bell RH Jr, Kuhlmann ET, Longnecker DS (1993) Derivation of ductlike cell lines from a transplantable acinar cell carcinoma of the rat pancreas. Am J Pathol 143:292-303
43. Ryschich E, Werner J, Gebhard MM, Klar E, Schmidt J (2003) Angiogenesis inhibition with TNP-470, 2-methoxyestradiol and paclitaxel in experimental pancreatic carcinoma. Pancreas 26:166-172
44. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265
45. Alsheikhly AR, Zweiri J, Walmesley AJ, Watson AJ, Christmas SE (2004) Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following "suicide" gene therapy in a murine colon carcinoma model. Cancer Immunol Immunother 53:946-954
46. Ito I, Ji L, Tanaka F, Saito Y, Gopalan B, Branch CD, Xu K, Atkinson EN, Bekele BN, Stephens LC, Minna JD, Roth JA, Ramesh R (2004) Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 11:733-739
47. Nomura T, Nakajima S, Kawabata K, Yamashita F, Takakura Y, Hashida M (1997) Intratumoral pharmacokinetics and in vivo gene expression of naked plasmid DNA and its cationic liposome complexes after direct gene transfer. Cancer Res 57:2681-2686
48. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, Henne Bruns D, Kremer B, Kalthoff H (2001) Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 7(3 Suppl):925s-932s
49. Ryschich E, Noetzel T, Hinz U, Autschbach F, Ferguson D, Simon I, Weitz J, Froelich B, Klar E, Buchler MW, Schmidt J (2005) Control of T-cell mediated immune response by HLA class I in human pancreatic carcinoma. Clin Cancer Res 11:498-504
50. de Visser KE, Kast WM (1999) Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 13(8):1188-1199
51. Inaba K, Witmer-Pack M, Inaba M, Hathcock KS, Sakuta H, Azuma M, Yagita H, Okumura K, Linsley PS, Ikehara S (1994) The tissue distribution of the B7-2 costimulator in mice: Abundant expression on dendritic cells in situ and during maturation in vitro. J Exp Med 180:1849-1860